ArticleWorld journal of gastrointestinal oncology2012
Relationship between HER-2 overexpression and brain metastasis in esophageal cancer patients.
Article in World journal of gastrointestinal oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Clinical outcome and molecular characterization of brain metastases from esophageal and gastric cancer: a systematic review.Medical oncology (Northwood, London, England) · 2017Pooled it
- Brain Metastases from Esophageal Cancer: A Retrospective Review from a Single Institution.World neurosurgery · 2025Article
- Leptomeningeal carcinomatosis and brain metastases in gastroesophageal carcinoma: a real-world analysis of clinical and pathologic characteristics and outcomes.Journal of neuro-oncology · 2024Article
- Clinical features and outcomes of advanced HER2+ esophageal/GEJ cancer with brain metastasis.ESMO open · 2024Article
- HER2-Positive Gastroesophageal Cancers Are Associated with a Higher Risk of Brain Metastasis.Cancers · 2022Article
- Outcomes and Molecular Features of Brain Metastasis in Gastroesophageal Adenocarcinoma.JAMA network open · 2022Article
- Enrichment ofThe oncologist · 2019Article
- Long-term survival after multidisciplinary therapy for brain metastases from asymptomatic esophageal adenocarcinoma.Clinical journal of gastroenterology · 2018Article
- Patterns of Distant Metastasis Between Histological Types in Esophageal Cancer.Frontiers in oncology · 2018Article
- SATB1 plays an oncogenic role in esophageal cancer by up-regulation of FN1 and PDGFRB.Oncotarget · 2017Article
- Outcomes in patients with brain metastasis from esophageal carcinoma.Journal of gastrointestinal oncology · 2016Article
- Brain metastases in gastro-oesophageal adenocarcinoma: insights into the role of the human epidermal growth factor receptor 2 (HER2).British journal of cancer · 2015Article
- Incidence and treatment of brain metastasis in patients with esophageal carcinoma.World journal of gastroenterology · 2015Review
- HER2-positive, trastuzumab-resistant metastatic esophageal cancer presenting with brain metastasis after durable response to dual HER2 blockade: a case report.Journal of gastrointestinal oncology · 2014Article
- HER-2 Expression in Brain Metastases from Colorectal Cancer and Corresponding Primary Tumors: A Case Cohort Series.International journal of molecular sciences · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo study if HER-2 overexpression by locally advanced esophageal cancers increase the chance of brain metastasis following esophagectomy.
methodsWe retrospectively reviewed the medical records of esophageal cancer patients who underwent esophagectomy at University of Iowa Hospitals and Clinics between 2000 and 2010. Data analyzed consisted of demographic and clinical variables. The brain metastasis tissue was assayed for HER-2 overexpression utilizing the FDA approved DAKO Hercept Test(®).
resultsOne hundred and forty two patients were reviewed. Median age was 64 years (36-86 years). Eighty eight patients (62%) received neoadjuvant chemoradiotherapy. Pathological complete and partial responses were achieved in 17 (19%) and 71 (81%) patients. Cancer relapsed in 43/142 (30%) patients. The brain was the first site of relapse in 9/43 patients (21%, 95% CI: 10%-36%). HER-2 immunohistochemistry testing of the brain metastasis tissue showed that 5/9 (56%) cases overexpressed HER-2 (3+ staining).
conclusionHER-2 overexpression might be associated with increased risk of brain metastasis in esophageal cancer patients following esophagectomy. Further studies will be required to validate this observation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.